Evidence has emerged that intestinal dysbiosis is associated with diverse pathological processes, including diabetes, obesity, and inflammatory bowel disease. In this study, we demonstrated intestinal barrier disruption and aberrant mucosal immunity i...
Evidence has emerged that intestinal dysbiosis is associated with diverse pathological processes, including diabetes, obesity, and inflammatory bowel disease. In this study, we demonstrated intestinal barrier disruption and aberrant mucosal immunity in 5/6 nephrectomized mice and the effect of probiotics on these parameters, systemic inflammation, and the progression of CKD. In CKD mice, the expression of colon HSP 70, a key protein in intestinal barrier integrity, and tight junction protein claudin-1 was significantly decreased; however, pore-forming claudin-2 expression and the incidence of apoptosis in colon epithelial cells was increased. These changes were accompanied by increased permeability. Although the percentage of CD4+ Foxp3+ Tregs, essential for immune tolerance, was not different than that in control mice, the ratio of CX3CR1intermediate/CX3CR1high proinflammatory/resident macrophages was increased in the colon of CKD mice with higher cytokine expression. Orally administered Lactobacilli mixture partially mitigated CKD-induced “leaky gut,” restored colon epithelial HSP 70, claudin-1, and claudin-2 expression, and decreased apoptosis. Probiotic treatment restored the ratio of CX3CR1intermediate/CX3CR1high macrophages and increased the percentage of CD103+ CD11c+ regulatory dendritic cells, Tregs, in the colon. These changes suppressed systemic inflammation and kidney fibrosis. Our data showed that intestinal dysbiosis-associated gut barrier disruption and aberrant mucosal immunity may be important in the systemic inflammation and progressive fibrosis of CKD. Intestinal targeting may provide novel opportunities for CKD therapy.